PT Bundamedik TbkISX:BMHS +1.11%61 EBITDA Margin % is 11.97% as of Mar. 2026, which is 18% below its 10-year median of 14.68. GuruFocus rates ISX:BMHS with a GF Score™ of 61/100 and a GF Value™ of Rp304.24 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 665 Healthcare Providers & Services companies, PT Bundamedik Tbk ranks better than 58.35% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. PT Bundamedik Tbk's EBITDA for the
three
months ended in Mar. 2026 was Rp44,411 Mil. PT Bundamedik Tbk's Revenue for the
three
months ended in Mar. 2026 was Rp371,094 Mil. Therefore, PT Bundamedik Tbk's EBITDA margin for the quarter that ended in Mar. 2026 was 11.97%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
PT Bundamedik Tbk EBITDA Margin % Related Terms
PT Bundamedik Tbk EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for PT Bundamedik Tbk's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:BMHS vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, PT Bundamedik Tbk's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Bundamedik Tbk EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, PT Bundamedik Tbk's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where PT Bundamedik Tbk's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Bundamedik Tbk (ISX:BMHS) has a EBITDA Margin % of 11.97% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PT Bundamedik Tbk and its competitors. This is 18% below median its historical median of 14.68. Over the past decade, PT Bundamedik Tbk's EBITDA Margin % has ranged from 13.51 to 28.80. According to the industry distribution chart, PT Bundamedik Tbk ranks #277 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 41.7%.
Is PT Bundamedik Tbk's EBITDA Margin % too high?
PT Bundamedik Tbk's current EBITDA Margin % of 11.97% is 18% below median its 10-year median of 14.68. Over the past 10 years, this metric has ranged from a low of 13.51 to a high of 28.80. The Healthcare Providers & Services industry median EBITDA Margin % is 10.24. PT Bundamedik Tbk's value of 11.97% is 16.9% above this industry median. Based on the distribution chart, PT Bundamedik Tbk ranks #277 out of 665 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, PT Bundamedik Tbk has a GF Score™ of 61/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PT Bundamedik Tbk's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, PT Bundamedik Tbk ranks #277 out of 665 companies for EBITDA Margin %. This puts PT Bundamedik Tbk in the upper half of its industry. The industry median EBITDA Margin % is 10.24. PT Bundamedik Tbk's value of 11.97% is 16.9% above this benchmark. Historically, PT Bundamedik Tbk's own EBITDA Margin % has ranged from 13.51 to 28.80 over the past decade. While the company's 10-year median is 14.68 vs. the industry median of 10.24, PT Bundamedik Tbk has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.24, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Bundamedik Tbk's current EBITDA Margin % of 11.97% is 16.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on PT Bundamedik Tbk and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Bundamedik Tbk's current EBITDA Margin % is 11.97%, which is 18% below median its own 10-year median of 14.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Bundamedik Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Bundamedik Tbk (ISX:BMHS) is currently considered Possible Value Trap. The stock's GF Value™ is Rp304.24, compared to a current price of Rp182.00 — trading 40.2% below its estimated fair value. The current EBITDA Margin % is 11.97%, which is 18% below median its 10-year median of 14.68 and 16.9% above the Healthcare Providers & Services industry median of 10.24. PT Bundamedik Tbk's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For PT Bundamedik Tbk (ISX:BMHS), the current EBITDA Margin % is 11.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Bundamedik Tbk (ISX:BMHS) Overvalued in 2026?
Based on GuruFocus' analysis, PT Bundamedik Tbk stock appears to be undervalued.
The current stock price of Rp182.00 is trading 40.2% below its estimated GF Value™ of Rp304.24.
GuruFocus considers PT Bundamedik Tbk to be Possible Value Trap.
Key valuation signals for ISX:BMHS:
EBITDA Margin %: 11.97% (18% below median its 10-year median of 14.68)
GF Value™: Rp304.24 vs. price of Rp182.00 (40.2% below fair value)
Industry Position: 16.9% above the Healthcare Providers & Services median (#277 of 665)
No single metric tells the full story. See the ISX:BMHS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Bundamedik Tbk is a healthcare service provider. The Company carries out its main business activities through private hospital activities. It offers maternal and child health services, outpatient services, inpatient services, emergency services, service excellence centers, IVF services, and Clinical laboratory services.
61GF Score
Get the complete analysis for ISX:BMHS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:BMHS has been successfully added to your 
